Skip to main content

Advertisement

Springer Nature Link
Log in

Expression of SOCSs in human prostate cancer and their association in prognosis

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Suppressors of cytokine signaling (SOCS) proteins have been identified as negative feedback regulators of cytokine-mediated signaling in various tissues, and demonstrated to play critical roles in tumorigenesis and tumor development of different cancers. The involvement of SOCSs in human prostate cancer (PCa) has not been fully elucidated. Thus, the aim of this study is to investigate the expression patterns and the clinical significance of SOCSs in PCa. The expression changes of SOCSs at mRNA and protein levels in human PCa tissues compared with adjacent benign prostate tissues were, respectively, detected by using real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) and immunohistochemistry analyses. The associations of SOCSs expression with clinicopathological features and clinical outcome of PCa patients were further statistically analyzed. Among SOCSs, both QRT-PCR and immunohistochemistry analyses found that SOCS2 expression was upregulated (at mRNA level: change ratio = 1.98, P = 0.031; at protein level: 5.12 ± 0.60 vs. 2.68 ± 0.37, P = 0.016) and SOCS6 expression was downregulated (at mRNA level: change ratio = −1.65, P = 0.008; at protein level: 3.03 ± 0.32 vs. 4.0.72 ± 0.39, P = 0.004) in PCa tissues compared with those in non-cancerous prostate tissues. In addition, the upregulation of SOCS2 in PCa tissues was correlated with the lower Gleason score (P < 0.001), the absence of metastasis (P < 0.001) and the negative PSA failure (P = 0.009); the downregulation of SOCS6 tended to be found in PCa tissues with the higher Gleason score (P = 0.016), the advanced pathological stage (P = 0.007), the positive metastasis (P = 0.020), and the positive PSA failure (P = 0.032). Furthermore, both univariate and multivariate analyses showed that the downregulation of SOCS2 was an independent predictor of shorter biochemical recurrence-free survival. Our data offer the convincing evidence for the first time that the dysregulation of SOCS2 and SOCS6 may be associated with the aggressive progression of PCa. SOCS2 may be potential markers for prognosis in PCa patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
€32.70 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Finland)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

  2. Klotz L (2000) Hormone therapy for patients with prostate carcinoma. Cancer 88:3009–3014

    Article  PubMed  CAS  Google Scholar 

  3. Eisenberger MA, Blumenstein BA, Crawford ED (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036–1042

    Article  PubMed  CAS  Google Scholar 

  4. Fitzgerald JS, Toth B, Jeschke U, Schleussner E, Markert UR (2009) Knocking off the suppressors of cytokine signaling (SOCS): their roles in mammalian pregnancy. J Reprod Immunol 83:117–123

    Article  PubMed  CAS  Google Scholar 

  5. Piessevaux J, Lavens D, Peelman F, Tavernier J (2008) The many faces of the SOCS box. Cytokine Growth Factor Rev 19:371–381

    Article  PubMed  CAS  Google Scholar 

  6. Linossi EM, Nicholson SE (2012) The SOCS box-adapting proteins for ubiquitination and proteasomal degradation. IUBMB Life 64:316–323

    Article  PubMed  CAS  Google Scholar 

  7. Sutherland KD, Lindeman GJ, Choong DY et al (2004) Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23:7726–7733

    Article  PubMed  CAS  Google Scholar 

  8. Tischoff I, Hengge UR, Vieth M et al (2007) Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett’s adenocarcinoma. Gut 56:1047–1053

    Article  PubMed  CAS  Google Scholar 

  9. Suzuki M, Shigematsu H, Shivapurkar N et al (2006) Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett 242:222–230

    Article  PubMed  CAS  Google Scholar 

  10. Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 28:886–892

    Article  PubMed  CAS  Google Scholar 

  11. Neuwirt H, Puhr M, Santer FR et al (2009) Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through downregulation of cyclins and cyclin-dependent kinases. Am J Pathol 174:1921–1930

    Article  PubMed  CAS  Google Scholar 

  12. Singh AP, Bafna S, Chaudhary K et al (2008) Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett 259:28–38

    Article  PubMed  CAS  Google Scholar 

  13. Horndasch M, Culig Z (2011) SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells. Prostate 71:1357–1366

    PubMed  CAS  Google Scholar 

  14. Sasi W, Jiang WG, Sharma A, Mokbel K (2010) Higher expression levels of SOCS 1, 3, 4, 7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer 10:178

    Article  PubMed  Google Scholar 

  15. Yoon S, Yi YS, Kim SS, Kim JH, Park WS, Nam SW (2012) SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues. Tumour Biol 33:215–221

    Article  PubMed  CAS  Google Scholar 

  16. Lai RH, Hsiao YW, Wang MJ, Lin HY, Wu CW, Chi CW, Li AF, Jou YS, Chen JY (2010) SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett 288:75–85

    Article  PubMed  CAS  Google Scholar 

  17. Storojeva I, Boulay JL, Ballabeni P, Buess M, Terracciano L, Laffer U, Mild G, Herrmann R, Rochlitz C (2005) Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer. Oncology 68:246–255

    Article  PubMed  CAS  Google Scholar 

  18. He HC, Zhu JG, Chen XB, Chen SM, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH, Zhong WD (2012) MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. FEBS Lett 586:2451–2458

    Article  PubMed  CAS  Google Scholar 

  19. Yasukawa H, Sasaki A, Yoshimura A (2000) Negative regulation of cytokine signaling pathways. Annu Rev Immunol 18:143–164

    Article  PubMed  CAS  Google Scholar 

  20. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256–269

    Article  PubMed  Google Scholar 

  21. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z (2007) Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer 14:1007–1019

    Article  PubMed  CAS  Google Scholar 

  22. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z (2006) Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 169:2199–2208

    Article  PubMed  CAS  Google Scholar 

  23. Pierconti F, Martini M, Pinto F, Cenci T, Capodimonti S, Calarco A, Bassi PF, Larocca LM (2011) Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate 71:318–325

    Article  PubMed  CAS  Google Scholar 

  24. Giri D, Ittmann M (2001) Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 159:139–147

    Google Scholar 

  25. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z (2000) Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 191:239–244

    Article  PubMed  CAS  Google Scholar 

  26. Chen JH, He HC, Jiang FN, Militar J, Ran PY, Qin GQ, Cai C, Chen XB, Zhao J, Mo ZY, Chen YR, Zhu JG, Liu X, Zhong WD (2012) Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population. Med Oncol 29:1972–1984

    Article  PubMed  CAS  Google Scholar 

  27. Rico-Bautista E, Flores-Morales A, Fernández-Pérez L (2006) Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev 17:431–439

    Article  PubMed  CAS  Google Scholar 

  28. Okano T, Xuan S, Kelley MW (2011) Insulin-like growth factor signaling regulates the timing of sensory cell differentiation in the mouse cochlea. J Neurosci 31:18104–18118

    Article  PubMed  CAS  Google Scholar 

  29. Leung KC, Doyle N, Ballesteros M et al (2003) Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 100:1016–1021

    Article  PubMed  CAS  Google Scholar 

  30. Sen B, Peng S, Woods DM et al (2012) STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res 18:127–139

    Article  PubMed  CAS  Google Scholar 

  31. Hendriksen PJ, Dits NF, Kokame K et al (2006) Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66:5012–5020

    Article  PubMed  CAS  Google Scholar 

  32. Hagiwara N (2011) Sox6, jack of all trades: a versatile regulatory protein in vertebrate development. Dev Dyn 240:1311–1321

    Google Scholar 

  33. Storojeva I, Boulay JL, Ballabeni P et al (2005) Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer. Oncology 68:246–255

    Article  PubMed  CAS  Google Scholar 

  34. Hwang MN, Min CH, Kim HS et al (2007) The nuclear localization of SOCS6 requires the N-terminal region and negatively regulates Stat3 protein levels. Biochem Biophys Res Commun 360:333–338

    Article  PubMed  CAS  Google Scholar 

  35. Hwang MN, Ha TH, Park J et al (2007) Increased SOCS6 stability with PMA requires its N-terminal region and the Erk pathway via Pkcdelta activation. Biochem Biophys Res Commun 354:184–189

    Article  PubMed  CAS  Google Scholar 

  36. Sriram KB, Larsen JE, Savarimuthu Francis SM et al (2012) Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS ONE 7:e30398

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by Grants from National Natural Science Foundation of China (81170699, 81272813, 81200550), Guangdong Provincial Science and Technology Project (2012B031800008), Medical Research Fund of Guangdong Province (A2012489), International scientific and technological cooperation projects of Guizhou Province (20117037), Joint Fund for Science and Technology Agency of Guizhou Province (20103116).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Urology, Guizhou Provincial People’s Hospital, Guizhou, 550002, China

    Jian-guo Zhu, Wei-hong Chen & Zhao-lin Sun

  2. Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, 510515, China

    Jian-guo Zhu, Qi-shan Dai & Wei-de Zhong

  3. Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, 510180, China

    Qi-shan Dai, Zhao-dong Han, Hui-chan He, Ru-jun Mo, Guo Chen, Yan-fei Chen, Yong-ding Wu, Sheng-bang Yang, Fu-neng Jiang & Wei-de Zhong

  4. Urology Key Laboratory of Guangdong Province, Guangzhou Medical University, Guangzhou, 510230, China

    Wei-de Zhong

Authors
  1. Jian-guo Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qi-shan Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhao-dong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui-chan He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ru-jun Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guo Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yan-fei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yong-ding Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sheng-bang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fu-neng Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wei-hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zhao-lin Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Wei-de Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei-de Zhong.

Additional information

Jian-guo Zhu and Qi-shan Dai contributed equally to this study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

11010_2013_1687_MOESM1_ESM.tif

Supplement Figure 1. Immunohistochemical staining for SOCS3, SOCS5 and PSA in PCa and benign prostate tissue (Original magnification ×200). A, SOCS3 moderately positive staining was found in cytoplasm of adjacent benign tissue; B, SOCS3 moderately positive staining was found in cytoplasm of PCa tissues; C, SOCS5 weakly positive staining was found in cytoplasm of adjacent benign tissue; D, SOCS5 weakly positive staining was found in cytoplasm of PCa tissues; PSA strongly positive staining in cytoplasm of PCa (E) and benign prostate tissue (F) as a positive control. Supplementary material 1 (TIFF 15227 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhu, Jg., Dai, Qs., Han, Zd. et al. Expression of SOCSs in human prostate cancer and their association in prognosis. Mol Cell Biochem 381, 51–59 (2013). https://doi.org/10.1007/s11010-013-1687-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-013-1687-6

Keywords

Search

Navigation